27 octobre 2023•Calcul en cours...

SEC amends Schedule 13D and 13G beneficial ownership reporting requirements

On October 10, 2023, the U.S. Securities and Exchange Commission (SEC) adopted final rules1 to amend beneficial ownership2 reporting requirements under the U.S. Securities Exchange Act (Exchange Act) to, among other things, shorten the deadlines for Schedule 13D and 13G filings.

Similar to the early warning reporting and alternative monthly reporting filings required to be made under Canadian securities laws, Schedule 13D and 13G filings provide transparency to the market that an investor, or a group of investors, has accumulated or holds a significant stake in the voting equity securities of any domestic or foreign issuer that has securities listed on a U.S. national securities exchange or otherwise has a class of equity securities registered under Section 12 of the Exchange Act3 (a U.S. reporting company).

What you need to know

  • The SEC has significantly shortened the Schedule 13D and Schedule 13G filing deadlines. For example, the initial Schedule 13D, and the initial Schedule 13G for passive investors4,will be due 5 business days (versus 10 calendar days) after crossing the 5% threshold. Initial Schedule 13G filings for Qualified Institutional Investors (QIIs)5 and exempt investors6 will also be accelerated from the current rules, as described in more detail below.
  • The SEC has also made changes to its deadlines for Schedule 13D and 13G amendments. For example, Schedule 13D amendments, and Schedule 13G amendments for passive investors exceeding the 10% threshold, will be due within 2 business days of the triggering event (versus “promptly” under the current rules). The deadlines for amendments have also been shortened for QIIs and exempt investors, as described in more detail below.
  • Investors in companies that are both Canadian reporting issuers and U.S. reporting companies, including Canadian companies relying on the multijurisdictional disclosure system (MJDS), need to be mindful of the reporting thresholds, deadlines and other requirements under both the Canadian and U.S. regimes. We have included a chart comparing the U.S. and Canadian filing deadlines at the end of this bulletin.
  • In addition to the shortened deadlines, the SEC clarified disclosure requirements regarding holders of certain cash-settled derivatives to remove any implication that a securityholder is not required to disclose their interest in cash-settled derivatives.
  • The SEC also provided clarifying guidance on the circumstances where a “group” may be found to have been formed and become subject to Section 13 reporting obligations.

Background

Schedule 13D is the U.S. equivalent of a Canadian early warning report. An initial Schedule 13D report must be filed following the acquisition of beneficial ownership of more than 5% of a class of a U.S. reporting company’s voting equity securities by a person or group (a purchaser) that has or is deemed to have “control intent” in respect of the issuer.

Schedule 13G is a short-form filing that may be used in lieu of Schedule 13D by QIIs, passive investors and exempt investors with no “control intent” (in the case of QIIs and passive investors) to report ordinary course beneficial ownership of more than 5% of a U.S. reporting company’s voting equity securities. Schedule 13G is the U.S. equivalent of the Canadian alternative monthly report that certain “eligible institutional investors” may be permitted to file instead of an early warning report.

Schedule 13D must be amended to report any material changes in the information reported, such as an increase or decrease in the purchaser’s holdings of 1% or more of the issuer’s outstanding voting equity securities. Schedule 13G must also be amended to report changes in beneficial ownership each year, or more frequently upon QIIs and passive investors crossing the 10% threshold, or to report an increase or decrease of 5% beneficial ownership.

Filing deadlines to be shortened

The SEC’s final rules accelerate many of the initial filing deadlines for Schedule 13D and Schedule 13G, as follows:

  • For Schedule 13D filers, the initial filing deadline is shortened to 5 business days (versus 10 calendar days under the existing rules) after crossing the 5% beneficial ownership reporting threshold.
  • For passive investors, the initial Schedule 13G filing deadline is likewise shortened to 5 business days (versus 10 calendar days under the existing rules) after crossing the 5% beneficial ownership threshold7.
  • For QIIs with beneficial ownership exceeding 10%, the initial Schedule 13G (or an amendment to their existing Schedule 13G, if previously over 5%) will be due within 5 business days after month-end in which the 10% threshold was crossed and thereafter upon a 5% increase or decrease in beneficial ownership (versus within 10 calendar days after month-end under the current rules).
  • For QIIs with beneficial ownership of 5% or more, but not more than 10%, and for exempt investors that cross the 5% threshold, the filing deadline for their initial Schedule 13G is accelerated to 45 calendar days after quarter-end (versus 45 calendar days after year-end) in which the 5% threshold is crossed.

Under the new rules, the deadlines for amendments to a previously filed Schedule 13D and 13G filing have also been changed:

  • Schedule 13D amendments must be filed within 2 business days (versus the current requirement to file “promptly”, a term that has been open to interpretation by market participants)8.
  • Passive investors will be required to file an amendment to their existing Schedule 13G within 2 business days of crossing the 10% threshold and thereafter upon a 5% increase or decrease in beneficial ownership (versus “promptly” under the current rules).
  • QIIs will be required to file an amendment to their existing Schedule 13G, if previously over 5%, within 5 business days after the end of the month in which the 10% threshold is crossed or a 5% increase or decrease in beneficial ownership occurred (versus 10 calendar days after month-end under the current rules).
  • The filing deadline for all other Schedule 13G amendments has been accelerated to 45 calendar days after quarter-end (versus 45 calendar days after year-end under the existing rules).
  • The new SEC rules have also limited Schedule 13G amendments to only report “material” changes (deemed to include an increase or decrease of beneficial ownership of 1% or more), which aligns with the standard for amendments by Schedule 13D filers (versus the requirement under the existing rules to report “any” change).

The SEC’s final rules also extend the filing cut-off times for Schedule 13D and Schedule 13G from 5:30 p.m. to 10:00 p.m. Eastern time.

In addition, to make it easier for investors and markets to use the information disclosed on Schedule 13D and Schedule 13G, the SEC’s final rules require these filings to use a structured, machine-readable, XML-based language (also known as XBRL). This requirement applies to all information disclosed on Schedule 13D and Schedule 13G, other than exhibits.

Treatment of cash-settled derivatives

Cash-settled equity derivatives generally are not included in the calculation of “beneficial ownership” for Section 13 reporting purposes because such securities do not give the holder thereof the “right to acquire” any voting equity securities of a U.S. reporting company. While the SEC did not adopt any rule changes that would have deemed certain holders of cash-settled derivative securities as beneficial owners for Section 13 reporting purposes, the SEC has instead revised Item 6 of Schedule 13D to require the disclosure of interests in cash-settled derivatives.

Under the current rules, Item 6 of Schedule 13D requires disclosure of “any contracts, arrangements, understandings, or relationships (legal or otherwise) … with respect to any securities of the issuer …” Under the new rules, Item 6 will now expressly require disclosure of any contracts, arrangements, understandings or relationships with respect to any class of a U.S. reporting company’s voting equity securities used as a reference security in connection with any call options, put options, security-based swaps or any other derivative securities.

In the adopting release for the new Section 13 rules, the SEC indicated that it wanted to dispel any implication that “with respect to securities of the issuer” could be read to suggest that contracts, arrangements, understandings or relationships that only create economic exposure to a U.S. reporting company’s voting equity securities or are otherwise synthetic did not need to be disclosed under Item 6 or that the derivative security had to have originated with the U.S. reporting company or otherwise be part of its capital structure in order to be disclosable under that item.

Group beneficial ownership reporting

Sections 13(d)(3) and (g)(3) of the Exchange Act provide that, when two or more persons act as a group “for the purpose of acquiring, holding or disposing of securities of an issuer”, the group is treated as a single person for purposes of calculating beneficial ownership of the relevant securities. Among other things, this means that the group members’ holdings and transactions in the issuer’s securities are aggregated for purposes of determining when and how the reporting thresholds apply. There is no definition of “group” in the SEC rules, and the determination of whether coordinated efforts among two or more persons constitute a group subject to regulation as a single person is a question of fact that, historically, has been resolved through case law.

In the adopting release, the SEC has provided extensive guidance on the application of the current rules on group formation. The guidance provides a range of examples on activities between shareholders that would not constitute the formation of a group. These examples include:

  • shareholders communicating with each other regarding an issuer without taking any action;
  • two or more shareholders engaging in discussions with an issuer’s management without taking any other action;
  • shareholders jointly making recommendations to an issuer regarding the issuer’s board of directors where no discussion of individual directors or board expansion occurs and no commitments are made, or agreements or understandings are reached, among the shareholders;
  • shareholders jointly submitting a non-binding shareholder proposal to an issuer;
  • a conversation, email, phone contact or meeting between a shareholder and an activist investor that is seeking support for its proposals to an issuer’s board or management, without further action; and
  • an announcement or a communication by a shareholder of the shareholder’s intention to vote in favor of an unaffiliated activist investor’s director nominees, without further action.

However, the SEC guidance has identified one scenario where a “group” would be deemed to be formed. If a shareholder who is (or would be) required to file on Schedule 13D intentionally communicates to a person that such a filing will be made, with the intention of causing that person to make purchases of the same security—and that person, as a result of that communication, makes purchases of the suggested security—this would result in a group being formed.

In addition to the above guidance, the SEC has also adopted new rules regarding group reporting that will attribute acquisitions of additional equity securities by group members to the group at any time after the group has been formed.

Effectiveness date

The amendments will become effective 90 days after publication of the adopting release in the Federal Register. Compliance with the revised Schedule 13G filing deadlines will be required beginning on September 30, 2024. Compliance with the machine-readable, XML requirements will be required beginning on December 18, 2024.

Comparison of U.S. and Canadian beneficial ownership reporting requirements

U.S. Schedule 13D versus Canadian Early Warning Reporting System (EWRS)

Current SEC Rule

2023 SEC Final Rule

Canadian Rule

Initial Filing Deadline

Within 10 calendar days after acquiring beneficial ownership of greater than 5% or losing eligibility to file on Schedule 13G.

Within 5 business days after acquiring beneficial ownership of greater than 5% or losing eligibility to file on Schedule 13G.

After acquiring beneficial ownership of, or control or direction over, 10% or more of a class of voting or equity securities, becoming disqualified from filing or electing to no longer file under the alternative monthly reporting system (AMRS) (see Schedule B below):

  • issue a news release promptly (but no later than the opening of trading on the next business day); and
  • file an early warning report (EWR) promptly (but no later than 2 business days).

Amendment Triggering Event

“Material” change in facts set out in previous Schedule 13D. A beneficial ownership increase or decrease of 1% or more is deemed to be “material”9.

No change proposed.

Acquisition or disposition of beneficial ownership, or acquisition or disposition of control or direction over:

  • securities equal to 2% or more of the class that was the subject of acquiror’s most recent report10; or
  • securities convertible into 2% or more of the outstanding securities referred to above11.

Change in a material fact in acquiror’s most recent report.

Beneficial ownership, or control or direction over, outstanding securities of class that was the subject of acquiror’s most recent report drops below 10%12.

Amendment Filing Deadline

Promptly after the triggering event. (See Rule 13d-2(a)).

Within 2 business days after the triggering event.

Issue a news release promptly (but no later than the opening of trading on the next business day) and file an early warning report (EWR) promptly (but no later than 2 business days).

 

U.S. Schedule 13G for Qualified Institutional Investors (QIIs), Passive Investors and Exempt Investors versus Canadian Alternative Monthly Reporting System (AMRS) for Eligible Institutional Investors (EIIs)

Current SEC Rule

2023 SEC Final Rule

Canadian Rule

Initial Filing Deadline

QIIs and exempt investors: Within 45 calendar days after the calendar year-end in which beneficial ownership is greater than 5%, except for QIIs who initially cross the 10% threshold, who would be required to make their initial 13G filing 10 calendar days after the month-end in which the 10% threshold is crossed.

Passive investors: Within 10 calendar days after acquiring beneficial ownership of greater than 5%.

QIIs and exempt investors: 45 calendar days after the calendar quarter-end in which beneficial ownership is greater than 5%, except for QIIs who initially cross the 10% threshold, who would be required to make their initial 13G filing 5 business days after the month-end in which the 10% threshold is crossed.

Passive investors: Within 5 business days after acquiring beneficial ownership of greater than 5%.

Non-disqualified EII: Within 10 days following the month-end in which:

  • the EII elects to file reports under AMRS, if its security holding % of a class of voting or equity securities is 10% or more; or
  • the EII’s security holding % of a class of voting or equity securities increased to 10% or more.

Amendment Triggering Event

All Schedule 13G filers: Any change in the information previously reported on Schedule 13G (other than a change in ownership percentage solely due to change in shares outstanding)13.

QIIs and passive investors: Upon exceeding 10% beneficial ownership or a 5% increase or decrease in beneficial ownership.

All Schedule 13G filers: Material change in the information previously reported on Schedule 13G (other than a change in ownership percentage solely due to change in shares outstanding)14. In alignment with the 13D definition of “material”, a beneficial ownership increase or decrease of 1% or more is deemed to be “material”.

QIIs and passive investors: Same as the current Schedule 13G.

Non-disqualified EII: Security holding % in a class of voting or equity securities, as at the month-end:

  • increased or decreased by 2.5% of the outstanding securities of the relevant class that is greater than 10%; or
  • decreased to less than 10%

Change in a material fact in the EII’s most recent report filed under the AMRS.

Amendment Filing Deadline

All Schedule 13G filers: 45 calendar days after the calendar-year end in which any change occurred.

QIIs: 10 calendar days after the month-end in which beneficial ownership exceeded 10% or there was, as of the month-end, a 5% increase or decrease in beneficial ownership.

Passive investors: Promptly after exceeding 10% beneficial ownership or a 5% increase or decrease in beneficial ownership.

All Schedule 13G filers: 45 calendar days after the calendar-quarter end in which a material change occurred.

QIIs: 5 business days after the month-end in which beneficial ownership exceeded 10% or there was, as of the month-end, a 5% increase or decrease in beneficial ownership.

Passive investors: 2 business days after exceeding 10% beneficial ownership or a 5% increase or decrease in beneficial ownership.

Within 10 days after month-end.


Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.

Développement de contre-mesures médicales au Canada

Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.

Exploiter les voies réglementaires mises en place lors de la pandémie de COVID-19

Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.

Le rôle de la Stratégie dans le renforcement du régime réglementaire de la santé au Canada

La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.

Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.

Prochaines étapes

Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.

Inscrivez-vous pour recevoir les dernières nouvelles

Restez à l’affût des nouvelles d’intérêt, des commentaires, des mises à jour et des publications de Torys.

Inscrivez-vous maintenant